- Home
- NVRI vs IOVA Comparison
NVRI vs IOVA Comparison
Compare NVRI & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- IOVA
- Stock Information
- Founded
- NVRI 1853
- IOVA 2007
- Country
- NVRI United States
- IOVA United States
- Employees
- NVRI N/A
- IOVA N/A
- Industry
- NVRI Diversified Commercial Services
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVRI Miscellaneous
- IOVA Health Care
- Exchange
- NVRI Nasdaq
- IOVA Nasdaq
- Market Cap
- NVRI 931.5M
- IOVA 975.1M
- IPO Year
- NVRI N/A
- IOVA N/A
- Fundamental
- Price
- NVRI $11.74
- IOVA $2.27
- Analyst Decision
- NVRI Hold
- IOVA Buy
- Analyst Count
- NVRI 1
- IOVA 11
- Target Price
- NVRI $10.00
- IOVA $11.90
- AVG Volume (30 Days)
- NVRI 1.2M
- IOVA 10.0M
- Earning Date
- NVRI 10-30-2025
- IOVA 11-06-2025
- Dividend Yield
- NVRI N/A
- IOVA N/A
- EPS Growth
- NVRI N/A
- IOVA N/A
- EPS
- NVRI N/A
- IOVA N/A
- Revenue
- NVRI $2,242,873,000.00
- IOVA $241,525,000.00
- Revenue This Year
- NVRI N/A
- IOVA $68.14
- Revenue Next Year
- NVRI $3.72
- IOVA $56.64
- P/E Ratio
- NVRI N/A
- IOVA N/A
- Revenue Growth
- NVRI N/A
- IOVA 636.99
- 52 Week Low
- NVRI $4.72
- IOVA $1.64
- 52 Week High
- NVRI $12.84
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- NVRI 52.50
- IOVA 48.89
- Support Level
- NVRI $11.53
- IOVA $2.09
- Resistance Level
- NVRI $12.09
- IOVA $2.38
- Average True Range (ATR)
- NVRI 0.42
- IOVA 0.12
- MACD
- NVRI -0.18
- IOVA 0.02
- Stochastic Oscillator
- NVRI 20.00
- IOVA 62.20
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.